Indian pharmaceutical companies seeking to export finished formulations to Brazil must navigate the regulatory framework established by the Agência Nacional de Vigilância Sanitária (ANVISA). The registration process involves several key steps:
1. Designating a Local Representative: Foreign companies cannot directly engage with ANVISA; they must appoint a legally established partner in Brazil to act as their local representative. This entity assumes legal responsibility for the imported products within Brazilian territory. (gov.br)
2. Obtaining Operating Licenses: The local representative must secure an Operating License (LF) from the local or state health surveillance authority. This license authorizes the company's activities, confirming compliance with legal and regulatory requirements.
3. Product Registration: Once the company is authorized to operate, the next step is registering the product with ANVISA. This involves submitting a comprehensive dossier that includes detailed information about the product's composition, manufacturing process, quality control measures, and clinical data demonstrating its safety and efficacy.
Regarding dossier formats, ANVISA accepts submissions in the Common Technical Document (CTD) format, which is internationally recognized and facilitates the review process. The approval timeline can vary; however, as of January 2025, ANVISA's Resolution No. 954 introduced a simplified procedure for drug registration, post-registration, and renewal, aiming to enhance regulatory process management and sanitary control within the pharmaceutical sector.
